A Subject-Blind, Investigator-Blind, Randomized, Placebo-Controlled, First-in-Human Study to Evaluate Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2018
At a glance
- Drugs UCB-0107 (Primary)
- Indications Alzheimer's disease; Progressive supranuclear palsy
- Focus Adverse reactions; First in man
- Sponsors UCB Biopharma
- 12 Jun 2018 Planned End Date changed from 31 Oct 2018 to 15 Nov 2018.
- 12 Jun 2018 Planned primary completion date changed from 31 Oct 2018 to 15 Nov 2018.
- 20 Mar 2018 New trial record